PE20090518A1 - Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) - Google Patents
Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)Info
- Publication number
- PE20090518A1 PE20090518A1 PE2008001261A PE2008001261A PE20090518A1 PE 20090518 A1 PE20090518 A1 PE 20090518A1 PE 2008001261 A PE2008001261 A PE 2008001261A PE 2008001261 A PE2008001261 A PE 2008001261A PE 20090518 A1 PE20090518 A1 PE 20090518A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- nos
- antigen
- receptor
- interleukin
- Prior art date
Links
- 102000003810 Interleukin-18 Human genes 0.000 title abstract 3
- 108090000171 Interleukin-18 Proteins 0.000 title abstract 3
- 102000025171 antigen binding proteins Human genes 0.000 title 1
- 108091000831 antigen binding proteins Proteins 0.000 title 1
- 230000001154 acute effect Effects 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 abstract 1
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 206010033647 Pancreatitis acute Diseases 0.000 abstract 1
- 206010033649 Pancreatitis chronic Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000003229 acute pancreatitis Diseases 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 102000043959 human IL18 Human genes 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000011505 plaster Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
Abstract
SE REFIERE A UNA PROTEINA ENLAZANTE DE ANTIGENO AISLADO TAL COMO UN ANTICUERPO MONOCLONAL HUMANIZADO QUE COMPRENDE A) UNA SECUENCIA DE AMINOACIDOS DE CADENA PESADA QUE CONTIENE AL MENOS UNA CDR SELECCIONADA DEL GRUPO DE: i) UNA CDRH1 DE CUALQUIERA DE LAS SEQ ID NOs 89, 92, 95, 98, 101, ENTRE OTROS; ii) UNA CDRH2 DE CUALQUIERA DE LAS SEQ ID NOs: 90, 93, 96, 99, 102, ENTRE OTROS; Y iii) UNA CDRH3 DE CUALQUIERA DE LAS SEQ ID NOs: 91, 94, 97, 100, 103, ENTRE OTROS; O B) UNA SECUENCIA DE AMINOACIDOS DE CADENA LIGERA QUE CONTIENE AL MENOS UNA CDR SELECCIONADA DEL GRUPO DE: i) UNA CDRL1 DE CUALQUIERA DE LAS SEQ ID NOs 140, 143, 146, 149, 152, ENTRE OTROS; ii) UNA CDRL2 DE CUALQUIERA DE LAS SEQ ID NOs: 141, 144, 147, 150, 153, ENTRE OTROS; Y iii) UNA CDRL3 DE CUALQUIERA DE LAS SEQ ID NOs: 142, 145, 148, 151, 154, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA DE DICHO ANTICUERPO. DICHA PROTEINA ENLAZANTE DE ANTIGENO AISLADO SE ENLAZA AL RECEPTOR DE LA INTERLEUCINA 18 (IL-18) HUMANA SIENDO UTIL PARA EL TRATAMIENTO DE PSORIASIS, LUPUS, HEPATITIS, PANCREATITIS CRONICA O AGUDA, ATAQUES CARDIACOS AGUDOS, RUPTURA DE LA PLACA ATEROMATOSA
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95169107P | 2007-07-24 | 2007-07-24 | |
| US95169207P | 2007-07-24 | 2007-07-24 | |
| US7314208P | 2008-06-17 | 2008-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090518A1 true PE20090518A1 (es) | 2009-04-25 |
Family
ID=40282148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001261A PE20090518A1 (es) | 2007-07-24 | 2008-07-24 | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8257707B2 (es) |
| EP (1) | EP2178917A4 (es) |
| JP (2) | JP2010534478A (es) |
| KR (1) | KR20100049535A (es) |
| CN (1) | CN101835489B (es) |
| AR (1) | AR067666A1 (es) |
| AU (1) | AU2008279127B2 (es) |
| BR (1) | BRPI0813016A2 (es) |
| CA (1) | CA2693503A1 (es) |
| CL (1) | CL2008002153A1 (es) |
| EA (1) | EA016783B1 (es) |
| IL (1) | IL202833A0 (es) |
| PE (1) | PE20090518A1 (es) |
| SG (1) | SG183070A1 (es) |
| TW (1) | TWI436778B (es) |
| WO (1) | WO2009015284A2 (es) |
| ZA (1) | ZA201001140B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| CN103080132B (zh) | 2010-08-25 | 2016-06-08 | 弗·哈夫曼-拉罗切有限公司 | 抗il-18r1的抗体及其用途 |
| CA2874721A1 (en) | 2012-05-30 | 2013-12-05 | Tomoyuki Igawa | Target tissue-specific antigen-binding molecule |
| US8821242B2 (en) | 2012-07-25 | 2014-09-02 | Lumos Labs, Inc. | Systems and methods for enhancing cognition |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
| KR102085179B1 (ko) * | 2013-05-07 | 2020-04-16 | 삼성전자주식회사 | 디바이스의 위치에 기초한 콘텐트 제공 시스템 및 방법 |
| JP6668241B2 (ja) | 2013-09-05 | 2020-03-18 | アムジエン・インコーポレーテツド | 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すＦｃ含有分子 |
| DK3078744T3 (da) | 2013-12-04 | 2020-09-28 | Chugai Pharmaceutical Co Ltd | Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne |
| EP3467501B1 (en) | 2014-05-16 | 2020-11-04 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
| CA2957814A1 (en) | 2014-08-20 | 2016-02-25 | Covidien Lp | Systems and methods for spherical ablations |
| KR20160047889A (ko) * | 2014-10-23 | 2016-05-03 | 삼성전자주식회사 | 전자 장치 및 피공유자 추천 서비스 운용 방법 |
| JP7672196B2 (ja) | 2017-03-14 | 2025-05-07 | アムジエン・インコーポレーテツド | 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節 |
| MX2020009907A (es) | 2018-03-26 | 2020-10-14 | Amgen Inc | Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular. |
| EP3810656A4 (en) * | 2018-06-19 | 2022-04-13 | Shanghaitech University | Human antibodies to human interleukin 18 receptor alpha and beta |
| MY202133A (en) | 2018-07-13 | 2024-04-05 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
| PE20210343A1 (es) | 2018-08-10 | 2021-02-23 | Chugai Pharmaceutical Co Ltd | Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso |
| MX2022003461A (es) | 2019-09-26 | 2022-04-19 | Amgen Inc | Metodos de produccion de composiciones de anticuerpos. |
| EP4162257A1 (en) | 2020-06-04 | 2023-04-12 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| MX2023004364A (es) | 2020-10-15 | 2023-05-03 | Amgen Inc | Glucanos no emparejados relativos en metodos de produccion de anticuerpos. |
| CN114736291B (zh) * | 2021-01-07 | 2023-08-11 | 中国科学院微生物研究所 | 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途 |
| WO2022261021A1 (en) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| CA3233279A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
| WO2023134767A1 (zh) * | 2022-01-14 | 2023-07-20 | 和径医药科技（上海）有限公司 | 一种靶向IL-18Rβ的抗体及其应用 |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024220916A1 (en) | 2023-04-20 | 2024-10-24 | Amgen Inc. | Methods of determining relative unpaired glycan content |
| WO2025038600A1 (en) | 2023-08-14 | 2025-02-20 | Amgen Inc. | Methods for reducing yellow color |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776731A (en) | 1996-02-21 | 1998-07-07 | Immunex Corporation | DNA encoding type-I interleukin-I receptor-like protein designated 2F1 |
| US7141393B2 (en) | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
| PT1047781E (pt) | 1998-01-23 | 2004-11-30 | Immunex Corp | Receptores de il-18 |
| WO1999037773A1 (en) | 1998-01-23 | 1999-07-29 | Immunex Corporation | Acpl dna and polypeptides |
| CA2340579A1 (en) * | 1998-09-01 | 2000-03-09 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin 18-binding protein |
| IL131047A0 (en) | 1999-07-22 | 2001-01-28 | Yeda Res & Dev | Use of il-18 inhibitors |
| AU7676300A (en) * | 1999-10-12 | 2001-04-23 | Cambridge Antibody Technology Limited | Human anti-adipocyte monoclonal antibodies and their use |
| EP2338515A3 (en) | 2000-02-10 | 2011-11-16 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
| ES2609583T3 (es) | 2000-06-16 | 2017-04-21 | Human Genome Sciences, Inc. | Anticuerpos que se unen inmunoespecíficamente a BLyS |
| AU2002211658A1 (en) | 2000-10-13 | 2002-04-22 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
| AU2002224417A1 (en) | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| KR100877033B1 (ko) | 2001-05-16 | 2009-01-07 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 패혈증의 치료 또는 예방을 위한 ｉｌ-18 저해물질의 용도 |
| WO2003057821A2 (en) | 2001-10-26 | 2003-07-17 | Centocor, Inc. | Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses |
| WO2003048328A2 (en) * | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibodies against carboxic anhydrase ix (ca ix) tumor antigen |
| CN100558895C (zh) * | 2003-07-18 | 2009-11-11 | 持田制药株式会社 | 抗血小板膜糖蛋白vi单克隆抗体 |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| DK1808446T3 (da) * | 2004-07-16 | 2012-05-14 | Atsuo Sekiyama | IL-18-receptor-antagonist og farmaceutisk sammensætning indeholdende antagonisten |
-
2008
- 2008-07-23 CL CL2008002153A patent/CL2008002153A1/es unknown
- 2008-07-24 US US12/670,112 patent/US8257707B2/en not_active Expired - Fee Related
- 2008-07-24 AR ARP080103206A patent/AR067666A1/es not_active Application Discontinuation
- 2008-07-24 KR KR1020107000286A patent/KR20100049535A/ko not_active Ceased
- 2008-07-24 JP JP2010518389A patent/JP2010534478A/ja not_active Ceased
- 2008-07-24 CN CN2008800254509A patent/CN101835489B/zh not_active Expired - Fee Related
- 2008-07-24 BR BRPI0813016A patent/BRPI0813016A2/pt not_active IP Right Cessation
- 2008-07-24 WO PCT/US2008/071047 patent/WO2009015284A2/en not_active Ceased
- 2008-07-24 SG SG2012054557A patent/SG183070A1/en unknown
- 2008-07-24 TW TW097128186A patent/TWI436778B/zh not_active IP Right Cessation
- 2008-07-24 AU AU2008279127A patent/AU2008279127B2/en not_active Ceased
- 2008-07-24 CA CA2693503A patent/CA2693503A1/en not_active Abandoned
- 2008-07-24 EP EP08826644A patent/EP2178917A4/en not_active Withdrawn
- 2008-07-24 EA EA201000238A patent/EA016783B1/ru not_active IP Right Cessation
- 2008-07-24 PE PE2008001261A patent/PE20090518A1/es not_active Application Discontinuation
-
2009
- 2009-12-20 IL IL202833A patent/IL202833A0/en unknown
-
2010
- 2010-02-17 ZA ZA2010/01140A patent/ZA201001140B/en unknown
-
2012
- 2012-08-20 US US13/589,984 patent/US8540993B2/en not_active Expired - Fee Related
-
2013
- 2013-09-03 US US14/017,014 patent/US20140093915A1/en not_active Abandoned
-
2014
- 2014-09-08 JP JP2014182029A patent/JP2015015957A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009015284A2 (en) | 2009-01-29 |
| KR20100049535A (ko) | 2010-05-12 |
| ZA201001140B (en) | 2011-03-30 |
| CA2693503A1 (en) | 2009-01-29 |
| BRPI0813016A2 (pt) | 2015-12-15 |
| CN101835489A (zh) | 2010-09-15 |
| US20140093915A1 (en) | 2014-04-03 |
| CL2008002153A1 (es) | 2009-06-05 |
| US20130034569A1 (en) | 2013-02-07 |
| WO2009015284A8 (en) | 2009-07-02 |
| AR067666A1 (es) | 2009-10-21 |
| IL202833A0 (en) | 2011-08-01 |
| US20110014201A1 (en) | 2011-01-20 |
| EP2178917A2 (en) | 2010-04-28 |
| AU2008279127B2 (en) | 2014-03-27 |
| SG183070A1 (en) | 2012-08-30 |
| JP2015015957A (ja) | 2015-01-29 |
| EP2178917A4 (en) | 2012-03-28 |
| AU2008279127A1 (en) | 2009-01-29 |
| US8257707B2 (en) | 2012-09-04 |
| EA201000238A1 (ru) | 2010-08-30 |
| US8540993B2 (en) | 2013-09-24 |
| TWI436778B (zh) | 2014-05-11 |
| EA016783B1 (ru) | 2012-07-30 |
| CN101835489B (zh) | 2013-10-16 |
| WO2009015284A3 (en) | 2009-10-01 |
| TW200927167A (en) | 2009-07-01 |
| JP2010534478A (ja) | 2010-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| MX2020013068A (es) | Anticuerpo anti proteína reguladora de señales alfa sirpalfana. | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| AR123305A2 (es) | Proteínas de unión a antígeno | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| AR086579A1 (es) | Proteinas de union a antigeno | |
| PE20080181A1 (es) | Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer | |
| JP2020500538A5 (es) | ||
| AR068723A1 (es) | Proteina que se une a antigenos que se une a il-23 humana y sus usos | |
| CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
| PE20140133A1 (es) | Nuevas proteinas de union a antigenos | |
| RU2017104815A (ru) | Молекулы со специфичностью в отношении cd79 и cd22 | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| PE20191131A1 (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos | |
| HRP20170882T1 (hr) | Humani antigen-vezujući proteini koji se vežu za beta-klotho, fgf receptore i njihove komplekse | |
| RU2017104813A (ru) | Молекулы со специфичностью к cd45 и cd79 | |
| JP2019504032A5 (es) | ||
| PE20090768A1 (es) | Metodos y composiciones para el tratamiento de enfermedades alergicas | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| PE20141660A1 (es) | PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |